08:39 AM EDT, 07/16/2024 (MT Newswires) -- Annovis Bio ( ANVS ) said Tuesday that the US Food and Drug Administration has granted the company approval to use a new crystalline form of its neurodegeneration drug buntanetap in future clinical studies.

The company said the approval permits Annovis to carry out a comparative study of the drug's forms in humans.

Shares of the company were up nearly 2.8% in recent Tuesday premarket activity.

Price: 12.99, Change: +0.35, Percent Change: +2.77